Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights ...

On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform"). As one of ...

Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future ...

Single B cell platforms have emerged as powerful tools for antibody discovery, enabling the rapid isolation and screening of ...

The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory systemic light chain amyloidosis, according to phase 1/phase 2 trial results ...

"If the light chains don't pair properly with the heavy chains because something is wrong with the antibody, we found that an unexpected secondary editing mechanism takes over, essentially swapping ...

In people with a rare condition called light chain amyloidosis, light chain proteins - which are a component of antibodies - mutate and build up in different organs. In new research published in The ...

Antibodies—proteins that are produced by our immune system to protect us—are crucial for recognizing and getting rid of unwanted substances, or antigens, in our body. Although their role is universal, ...

Ikoma, Japan – Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising ...